Autonomix announces approval of protocol amendment by ethics committee upon completion of all lead-in patients in ongoing human clinical trial

Company plans to release topline results from “lead-in” patients (n=5) imminently the woodlands, tx, june 03, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has received ethics committee approval of the protocol amendment for its ongoing proof-of-concept (poc) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. the primary objective of the poc human clinical trial is to successfully ablate relevant nerves and mitigate pain in patients with pancreatic cancer pain utilizing rf ablation in a transvascular approach to the nerves in the region.
AMIX Ratings Summary
AMIX Quant Ranking